亚辉龙

Sepsis, a life-threatening condition that arises when the body's response to infection causes tissue damage and organ failure, poses a significant global health challenge. World Sepsis Day serves as a global platform to unite healthcare professionals, organizations, and the public to educate about the early signs of sepsis, promote prevention strategies, and reduce the high mortality rates associated with it. Through widespread awareness efforts, World Sepsis Day helps spotlight the urgent need for improved sepsis care and research worldwide, emphasizing the importance of timely diagnosis and treatment. #WorldSepsisDay #YHLO #CLIA #iFlash #Diagnosis #Inflammation

🎉 Triple Celebrations at YHLO | Grand Opening of Qide Tower! 🎉 On September 10, Shenzhen YHLO officially inaugurated its second industrial park, Qide Tower, marking a major milestone in YHLO’s development. Chairman Mr. Hu Kunhui emphasized that this new facility not only symbolizes YHLO’s strength and ingenuity but also signifies the company’s deep commitment to exploring the future of medical technology. The event also highlighted two 🔑key milestones: 🅰The unveiling of the Peking University-YHLO Joint Laboratory for Molecular Diagnosis of Infectious Diseases. The joint laboratory has already made significant progress, including the development of diagnostic reagents for Hepatitis D antibody and nucleic acid testing, as well as large, medium, and small Hepatitis B virus surface antigen detection kits. The Hepatitis D virus antibody and nucleic acid test kits are expected to be officially launched next year. 🅱The official introduction of YHLO's independently developed iTLA Max Laboratory Automation System, a cutting-edge solution that combines AI and visual recognition technologies to enhance lab testing efficiency. The event was attended by distinguished guests, including Academician Zhuang Hui (Peking University Health Science Center), Academician Gu Dongfeng (Southern University of Science and Technology), Academician Zheng Zhongxuan (The Chinese University of Hong Kong, Shenzhen), Liu Wang (Hunan University of Technology), Zhou Zhou (Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS)), Song Haibo (founder of CACLP), Wang Hualiang (Shanghai Institute of Experimental Medicine), Li Xuejin (The Chinese University of Hong Kong, Shenzhen), Ito Hiroshi (Japan MBL Corporation), and Chen Xiaozi (district councilor of Tsuen Wan, Hong Kong). Located in Longgang District, Shenzhen, Qide Tower spans 109,000 square meters, integrating offices, R&D labs, production, and living spaces. Together with YHLO's first Biotech Tower, the facilities provide over 160,000 square meters of space to support YHLO's innovation and growth. With the grand opening of Qide Tower, YHLO is positioned for even greater growth and innovation in the IVD industry. These advancements reflect YHLO’s vision of shaping the future of medical technology while contributing to global healthcare progress. #YHLO #IVD #iTLA #Healthcare #CLIA #Hepatitis #HBV #HDV

YHLO iTLA MAX Laboratory Automation System has won the prestigious 2024 MUSE Design Awards Gold Prize, often referred to as the "OSCAR of the design world." This award highlights the system's innovative design and exceptional performance in automating laboratories, enhancing efficiency and safety. We're proud of this recognition from top international design professionals and remain committed to delivering high-quality solutions that advance the global healthcare industry. #Innovation #DesignExcellence #HealthcareAutomation #MUSEDesign #Awards

🌐 YHLO Receives First IVDR Class D CE Certification! 🌐 We are thrilled to announce that YHLO has successfully obtained its first IVDR Class D CE certification for our HBeAg diagnostic product in the field of liver disease. This certification, awarded by the British Standards Institution (BSI), marks a significant milestone, reaffirming the technical prowess and product quality of YHLO in the chemiluminescence domain. The CE certification is a vital passport for products entering the European Union (EU) market, ensuring they meet the stringent safety, performance, and quality standards as mandated by EU regulations. On May 5, 2017, the EU introduced the In Vitro Diagnostic Regulation (IVDR) (Regulation (EU) 2017/746) to safeguard public health by categorizing products based on risk levels, ranging from Class A (lowest risk) to Class D (highest risk), each subject to varying levels of regulatory oversight. As a leader in the in vitro diagnostics industry, YHLO remains dedicated to innovation and quality, continuously striving to improve healthcare services through advanced products and solutions. The acquisition of our first IVDR Class D CE certification is not only a prestigious honor but also a significant responsibility. Moving forward, we will remain steadfast in our mission to address clinical needs, working closely with BSI and other professional organizations and global partners to advance the development of high-quality healthcare worldwide. #HBeAg #IVDR #CE #ClassD #YHLO #CLIA #iFlash

The three-day Medlab East Africa medical exhibition concluded successfully today in Nairobi. At this event, YHLO showcased its iFlash series chemiluminescence immunoassay analyzers and the latest biochemical diagnostic equipment. These products garnered significant attention and widespread recognition from attendees for their outstanding detection performance and advanced automation technology. We extend our sincere thanks to all the customers and partners who visited our booth, as well as to everyone who has continuously supported YHLO’s development. Medlab East Africa provided us with an excellent platform to showcase our innovative diagnostic solutions strengthen our connection with the local market and advance our business expansion in Africa. YHLO will continue to provide superior diagnostic products and services to our global customers. We look forward to working with more partners in the future to promote the development of global healthcare jointly. #YHLO #medlab #east #africa #health #care #diagnostic

📜 This article investigates ovarian reserve in women with autoimmune conditions, focusing on primary antiphospholipid syndrome (PAPS), systemic lupus erythematosus-associated APS (SLE-APS), and SLE alone. The study highlights differences in ovarian reserve based on age, hormonal levels, and specific autoantibodies. It found that women with SLE-associated APS had significantly lower ovarian reserve compared to those with PAPS or SLE alone. AMH was identified as a key predictor of ovarian reserve decline, showing an inverse correlation with age and a positive correlation with inhibin B. The findings emphasize the importance of fertility monitoring and early intervention for women with these autoimmune conditions to better manage reproductive health risks.

YHLO is dedicated to realizing its vision "To be a reliable and respected IVD enterprise" by consistently delivering innovative and trustworthy diagnostic solutions that earn the trust of healthcare professionals worldwide. #IVD #Diagnosis #YHLO #CLIA

#YHLO #iFlash #InhibinB #FSH #NonObstructiveAzoospermia #TesticularSpermExtraction #TEST #Prediction

#YHLO #MaternalScreening #CLIA #iFlash

🌟 APLAR 2024: YHLO Leads a New Chapter in APS 🌟 #APLAR2024 #APS #YHLO #IVD #Autoimmunity